
CJC-1295 DAC, with the chemical formula C165H269N47O46 and CAS number 446262-90-4, is a synthetic peptide and a modified version of Growth Hormone-Releasing Hormone (GHRH). The inclusion of the Drug Affinity Complex (DAC) gives it a much longer half-life, which allows for more sustained release of growth hormone.
CJC-1295, with the chemical formula C152H252N44O42 and CAS number 863288-34-0, is another GHRH analog used in similar contexts but lacks the DAC component. As a result, it has a much shorter half-life, requiring more frequent administration to achieve similar effects to CJC-1295 DAC.
CJC-1295 and CJC-1295 DAC are both designed to stimulate the release of growth hormone from the pituitary gland. While they share similar effects, their key difference lies in the pharmacokinetics, specifically the half-life. The half-life of CJC-1295 without DAC is approximately 30 minutes to 1 hour, whereas CJC-1295 DAC has a significantly longer half-life of up to 8 days, making it a more convenient option for those who prefer less frequent injections.
Both CJC-1295 and CJC-1295 DAC are used primarily for their ability to stimulate the release of growth hormone, which plays a key role in muscle growth, fat loss, and overall metabolic health. Their use is primarily in clinical and research settings, particularly among those looking to enhance growth hormone levels for various health and performance goals. The difference between cjc with dac and without dac is described below.
CJC-1295, without the DAC modification, has a much shorter half-life, making it more suitable for users who are looking for rapid but frequent bursts of growth hormone. This form is typically administered multiple times a day or week to maintain consistent levels of growth hormone in the body. The peptide is popular among athletes and bodybuilders aiming to boost muscle growth, enhance recovery, and improve fat metabolism over short periods.
CJC-1295 can also be used in clinical settings for growth hormone replacement therapy (HGH therapy), particularly in individuals who suffer from growth hormone deficiencies or related disorders. Its shorter half-life makes it easier to control dosing schedules and adjust based on individual needs.
CJC-1295 DAC offers a distinct advantage for those who prefer less frequent injections. The DAC modification significantly extends the half-life of the peptide, allowing for sustained growth hormone release with fewer injections. This is particularly beneficial for individuals who do not want to commit to frequent dosing schedules, but still wish to enjoy the benefits of elevated growth hormone levels.
CJC-1295 DAC is commonly used by individuals in anti-aging treatments, weight management programs, and in research settings focusing on metabolic health. The prolonged release helps to maintain steady hormone levels, promoting muscle growth, fat burning, and improved sleep patterns without the need for constant administration.
Both peptides are widely used in weight loss regimens, particularly because growth hormone has been shown to promote fat breakdown and increase lean muscle mass. The ability to stimulate growth hormone release, particularly with the sustained action of CJC-1295 DAC, can aid in long-term weight management and fat reduction.
Individuals seeking weight loss benefits often find CJC-1295 DAC more convenient, as it eliminates the need for frequent injections. By stimulating the body's natural fat-burning processes, both peptides can enhance the effectiveness of diet and exercise programs aimed at reducing body fat and preserving lean muscle mass.
In summary, CJC-1295 DAC and CJC-1295 both offer effective means of stimulating growth hormone release, but they differ significantly in their pharmacokinetics. CJC-1295 DAC is ideal for those who want prolonged effects with less frequent injections, while CJC-1295 is suitable for those who prefer more immediate results with more frequent dosing. Both compounds have their respective applications in improving muscle growth, fat loss, and overall metabolic health, with the key difference being the duration of action.
| Disadvantage |
CJC-1295 DAC |
CJC-1295 |
|---|---|---|
| Frequency of Administration | Requires less frequent injections due to extended half-life | Requires more frequent injections to maintain growth hormone levels |
| Injection Site Discomfort | Minimal, as the slower release reduces discomfort | May cause discomfort due to more frequent injections |
| Cost | Typically higher due to the DAC modification | Lower cost compared to CJC-1295 DAC |
If you're looking to purchase these compounds, Guidechem is your go-to platform for sourcing high-quality raw materials and reliable suppliers. With our extensive global network, we connect you to a wide range of CJC-1295 DAC suppliers and CJC-1295 suppliers, ensuring you find the right products to meet your specific research or production requirements. Whether you're in pharmaceuticals, food additives, or other industries, Guidechem simplifies the sourcing process, offering verified supplier information, competitive pricing, and seamless communication.
[2]Peptide Synthesis and Applications in Clinical Medicine by J. Carter.
[4]The Role of Growth Hormone in Aging in Anti-Aging Journal.
![]() |